Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02063308 · ClinicalTrials.gov registry record · NA

Oxaloacetate Pharmacokinetics and Safety

A NA study of Alzheimers Disease, sponsored by Russell Swerdlow, MD.

Completed
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT02063308: Completed NA study of Alzheimers Disease, sponsored by Russell Swerdlow, MD.

NCT02063308 is a NA study of Alzheimers Disease that has completed, run by Russell Swerdlow, MD. The registered enrollment target is 6 participants, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02063308, a NA study of Alzheimers Disease, has completed, sponsored by Russell Swerdlow, MD.

COMPLETED
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's disease who take OAA for one month have any side-effects.

Primary Outcome

Baseline blood sample will be obtained before 100 mg OAA is administered. Blood samples to be drawn every 15 minutes starting 30 minutes after OAA administration.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Oxaloacetate (OAA)

Study Locations (1)

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2014-02
Est. Completion 2014-06
Phase NA
Russell Swerdlow, MD

2 total trials

What the finished NCT02063308 record still lists

NCT02063308 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which Oxaloacetate (OAA) is the first listed.

NCT02063308 reports a single indexed study location in Kansas.

Frequently Asked Questions

What is clinical trial NCT02063308 about?

NCT02063308 is a clinical study titled "Oxaloacetate Pharmacokinetics and Safety". By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's disease who take OAA for one month have any side-effects.

What is the current status of trial NCT02063308?

This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2014-02. Estimated completion is 2014-06.

What conditions does trial NCT02063308 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT02063308?

The interventions under investigation include: Oxaloacetate (OAA) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02063308?

This trial is sponsored by Russell Swerdlow, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02063308 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02063308's enrollment target sits among peer trials

6 146th of 147 higher than 1 of 147 other Alzheimers Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02063308, the US trial registry maintained by the National Library of Medicine. NCT02063308 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.